C11D 3/38681
Chemically modified or immobilised enzymes
Official title: {Chemically modified or immobilised enzymes}
C11D3/38681 (Chemically modified or immobilised enzymes) appears on 197 US grants and 418 published applications in this corpus.
Search patents in C11D- Granted patents
- 197
- Published applications
- 418
- Assignees
- 49
- Inventors
- 563
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 7 |
| 2003 | 3 | 3 |
| 2004 | 1 | 3 |
| 2005 | 2 | 5 |
| 2006 | 0 | 1 |
| 2007 | 1 | 3 |
| 2008 | 3 | 2 |
| 2009 | 3 | 7 |
| 2010 | 1 | 15 |
| 2011 | 5 | 21 |
| 2012 | 6 | 20 |
| 2013 | 10 | 11 |
| 2014 | 13 | 22 |
| 2015 | 8 | 30 |
| 2016 | 11 | 39 |
| 2017 | 8 | 28 |
| 2018 | 6 | 35 |
| 2019 | 18 | 35 |
| 2020 | 27 | 34 |
| 2021 | 12 | 20 |
| 2022 | 13 | 15 |
| 2023 | 9 | 10 |
| 2024 | 11 | 20 |
| 2025 | 12 | 15 |
| 2026 | 8 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Alpha-amylase variants and polynucleotides encoding same26 May 2026US 12,637,636 B2Novozymes A/S
- Subtilase variants and polynucleotides encoding same19 May 2026US 12,630,812 B2Novozymes A/S
- Compositions for inducing modifications of target endogenous nucleic acid sequences in nucleuses of eukaryotic cells28 Apr 2026US 12,612,632 B2Toolgen Incorporated
- Compositions for inducing modifications of target endogenous nucleic acid sequences in nucleuses of eukaryotic cells28 Apr 2026US 12,612,633 B2Toolgen Incorporated
- Compositions for inducing modifications of target endogenous nucleic acid sequences in nucleuses of eukaryotic cells28 Apr 2026US 12,612,634 B2Toolgen Incorporated
- Producing Engineered Cells by Introducing Cas9/sgRNA Complexes27 Aug 2026US 2026/0250690 A1Toolgen Incorporated
- Vitro and Ex Vivo Methods for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells13 Aug 2026US 2026/0234641 A1Toolgen Incorporated
- Methods for Modifying Endogenous Nucleic Acid Sequences via Electroporation13 Aug 2026US 2026/0234643 A1Toolgen Incorporated
- Methods for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells6 Aug 2026US 2026/0226478 A1Toolgen Incorporated
- Methods for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Non-Human Embryos6 Aug 2026US 2026/0226480 A1Toolgen Incorporated
Most cited
By later US patents
- Amylase variants108US 6,093,562 ANovo Nordisk A/S · 2000
- Amylase variants82US 6,297,038 B1Novozymes A/S · 2001
- Amylase variants63US 6,867,031 B2Novozymes A/S · 2005
- Polypeptides having haloperoxidase activity43US 6,506,585 B2Novozymes A/S · 2003
- Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein42US 10,851,380 B2Toolgen Incorporated · 2020